About European Vaccine Manufacturers


Our mission at European Vaccine Manufacturers (EVM) is threefold:

  1. Enhancing Vaccine Protection and Coverage: We strive to create a supportive environment that ensures improved vaccine protection and coverage, benefiting both individuals and the broader community’s public health.
  2. Promoting Vaccine Research and Development (R&D): We are committed to advancing vaccine R&D efforts, addressing emerging challenges, and fostering innovation in vaccine applications to combat various infectious and non-infectious diseases.
  3. Advocating for a Favorable Policy Climate: EVM actively works to promote a favorable policy landscape for the vaccine industry within Europe. By doing so, we facilitate the global distribution of new and critical vaccines.

EVM Membership

EVM’s membership comprises leading vaccine manufacturers, including:

  • Baxter – Austria
  • Berna (A Crucell Company) – Switzerland and Spain
  • GlaxoSmithKline Biologicals – Belgium
  • Novartis Vaccines – Italy and Germany
  • Sanofi Pasteur – France
  • Sanofi Pasteur MSD – France
  • Solvay Pharmaceuticals – The Netherlands
  • Wyeth Vaccines – Belgium

EVM Structure

The governance of EVM is structured as follows:

  • General Assembly: The General Assembly, convening annually, includes two representatives from each member company. It serves as the collective decision-making body.
  • EVM Board: The EVM Board, elected by the General Assembly, is responsible for defining EVM’s strategy and policies in alignment with EFPIA (European Federation of Pharmaceutical Industries and Associations) policies.

EVM Board Composition

The EVM Board is composed of dedicated professionals from member companies, and it includes the following positions:


  • President – Didier Hoch (Sanofi Pasteur MSD)
  • Treasurer – Jacques Berger (Sanofi Pasteur)


  • Denis Cavert (Baxter)
  • Ralf Clemens (Novartis Vaccines)
  • Ian Kingston (GlaxoSmithKline)
  • Kuno Sommer (Berna, A Crucell Company)
  • Herman van Heemstra (Solvay Pharmaceuticals)

Working Group Chairpersons:

EVM’s various Working Groups play a pivotal role in advancing our mission, and they are chaired by the following individuals:

  • Rudy Daems (Novartis Vaccines) – Chair of Public Health Policy Working Group
  • Bernard Fritzell (Wyeth) – Chair of Clinical and R&D Working Group
  • Anne-Marie Georges (Novartis Vaccines) – Chair of Regulatory Working Group
  • Luc Hessel (Sanofi Pasteur MSD) – Chair of Influenza Pandemic Working Group

EVM Working Groups

Our Working Groups, which report to the EVM Board, consist of experts in key areas:

  • Clinical and R&D
  • Influenza Pandemic
  • Public Health
  • Regulatory Affairs

Did You Know?

The European vaccine industry is a dynamic and impactful sector:

  • We are the world’s largest supplier of vaccines, responsible for producing approximately 80% of vaccines used globally.
  • EVM leads the way in supplying UNICEF with essential pediatric vaccines, including those against polio.
  • We have developed vaccines tailored to the unique needs of developing countries, such as combined pediatric vaccines addressing diphtheria, tetanus, pertussis, hepatitis B, and invasive Hib disease.
  • Collaboration with the public sector in joint R&D activities and clinical trial partnerships is a key part of our work. We focus on vaccines for diseases that disproportionately affect developing countries, including dengue fever, leishmaniasis, rotavirus, HIV, malaria, and tuberculosis, among others.
  • Over half of all global vaccine R&D takes place in Europe through our member companies, highlighting our commitment to innovation.
  • Our production facilities span the globe through international collaborations and joint ventures, ensuring widespread vaccine access.
  • We submit our novel products to a centralized procedure to obtain EU licensing, which includes vaccines against hepatitis B, hepatitis B-containing combination vaccines, pneumococcal conjugate vaccines, and more.

© European Vaccine Manufacturers (EVM) – a specialized group of EFPIA 2007